Print

Print


^^^^^^  WARM GREETINGS  FROM  ^^^^^^^^^^^^  :-)
 Ivan Suzman        50/39/36       [log in to unmask]      :-)
 Portland, Maine    land of lighthouses        46 rainy   deg. F   :-)
********************************************************************

--------- Forwarded message ----------
From: Ivan M Suzman <[log in to unmask]>
To: [log in to unmask]
Date: Wed, 18 Oct 2000 07:32:17 -0400
Subject: Re: JAMA: Pramipexole vs Levodopa as Initial Treatment for
PD/Tasmar's role
Message-ID: <[log in to unmask]>

Dear Dr.  Romero and PIEN friends,

   My pill-taking inner voice suggests
to  me that PWP's are better off (I am) if
they use Sinemet or Atamet , or  a generic brand
of L-dopa,  instead of pramipexole (otherwise known as
Mirapex), in any stage of Parkinson's Disease.

   For me, Mirapex, or pramipexole,
was way too strong, made me dizzy and
mentally confused in even a tiny dose.  It was
scary. Meanwhile,  L-dopa  still works pretty well.

    I hope physicians can pay close attention to your summary.

   Meanwhile, what I wonder is, how do we get Tasmar elevated
to proper respectability?  It has been a great medication
for me.   I think its supposed links to changes in liver
enzymes are only possible in  rare cases,
where physicians presecribed it in too high a dose,
before they realized how to use it

I use 300 mg per day (6 x 50 mg,).  Each 50 mg dose
is a 100 mg tablet, sliced in half.

Jorge, thank you for sharing on the PIEN list.
Incidentally, where do you practice?
Any Tasmar experience?

Thank you,

Ivan Suzman, PWP
50/39/36


On Tue, 17 Oct 2000 20:33:45 -0500 Jorge A Romero MD
<[log in to unmask]> writes:
> This study is very significant:
> > quality of life were BETTER in the Levo-dopa group than in the
> pramipexole
> group.
> 2)  The side effects of nausea, hallucinations, and sleepiness were
> more
> common in the pramipexole group than in the levodopa group.
> 3)  The PWP in the pramipexole group had fewer dyskinesias - BUT
> DESPITE THE
> FEWER DYSKINESIAS  they reported better quality of life with
> levodopa than
> with pramipexole at the end of the study.
>